论文部分内容阅读
作者通过对聚丙交酸-乙交酯(PLG)微球中丙交酯与乙交酯配比的研究以及对影响聚合物降解和内容物释放两项参数的研究,探讨了作为肽疫苗载体的PLG微球在免疫应答中的作用.作者合成了狂犬病病毒ERA株的部分核蛋白:多肽31D带有免疫显性辅助性T细胞表位;多肽V10c含有线性B细胞表位.此外,作者采用3种不同配方制备了3种PLG微球:(1)50/50.2 PLG微球:丙交酯:乙交酯为1:1,分子量为8000Da,微球直径为1～20μm;(2)50/50.74 PLG微球:丙交酯:乙交酯为1:1,分子量为60000Da,微球直径为10～60μm;(3)85/15 PLG微球:丙交酯:乙交酯为85:15,分子量为95000Da,微球直径为50～100μm.分别将31D多肽和31D与V10c多肽的结合物掺入3种PLG微球中制成含肽微球.用酯酶处理微球,用反向高效液相层析测定肽从PLG制剂中的相对释放率.结果显示,50/50.2 PLG制剂在酯
Through the study of the ratio of lactide to glycolide in poly (L-lactide-co-glycolide) (PLG) microspheres and the study of two parameters affecting the degradation and content release of polymer, PLG microspheres in immune response.We synthesized a partial nuclear protein of rabies virus ERA strain: polypeptide 31D with immunodominant helper T cell epitopes and polypeptide V10c with linear B cell epitopes.In addition, the authors used 3 Three kinds of PLG microspheres were prepared with different formulations: (1) 50/50. 2 PLG microspheres: lactide: glycolide 1: 1, molecular weight 8000Da and microspheres 1 ~ 50.74 PLG microspheres: lactide: glycolide 1: 1, molecular weight 60000Da, microspheres diameter 10 ~ 60μm; (3) 85/15 PLG microspheres: lactide: glycolide 85:15 , The molecular weight of 95000Da, the diameter of the microspheres was 50 ~ 100μm.The 31D polypeptide and the combination of 31D and V10c polypeptide were respectively incorporated into the three kinds of PLG microspheres to make peptide-containing microspheres.The microspheres were treated with esterase, The relative release rates of the peptides from the PLG formulation were determined by high performance liquid chromatography The results showed that the 50/50.2 PLG formulation exhibited higher esterification